We observed that the AML burden was statistically significantly lower in the BM (Figure 3, B and C; P = 0.001, 51.2% versus 2.3%), SP (Figure 3D; P = 0.026, 8.79% versus 0.84%), and PB (Figure 3E; P = 0.035,13.06% vs 0.24%) in the CD84 knockdown group compared with levels in the control recipient animals. This evidence concerns the gene CD84 and acute myeloid leukemia.